Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases.
M Taariq SalieJing YangCarlos R Ramírez MedinaLiesl J ZühlkeChishala ChishalaMpiko NtsekheBernard GituraStephen OgendoEmmy OkelloPeter LwabiJohn MusukuAgnes MtajaChristopher Hugo-HammanAhmed El-SayedAlbertino DamascenoAna MocumbiFidelia Bode-ThomasChristopher YilgwanGaniyu A AmusaEsin NkereuwemGasnat ShaboodienRachael Da SilvaDave Chi Hoo LeeSimon FrainNophar GeifmanAnthony D WhettonBernard KeavneyMark M Engelnull nullPublished in: Clinical proteomics (2022)
These results support the presence of an ongoing inflammatory response in RHD, at a time when severe valve disease has developed, and distant from previous episodes of acute rheumatic fever. This biomarker signature could have potential utility in recognizing different degrees of ongoing inflammation in RHD patients, which may, in turn, be related to prognostic severity.
Keyphrases
- inflammatory response
- end stage renal disease
- mass spectrometry
- oxidative stress
- rheumatoid arthritis
- drug induced
- chronic kidney disease
- early onset
- peritoneal dialysis
- liver failure
- aortic valve
- prognostic factors
- respiratory failure
- genome wide
- lymph node
- electronic health record
- liquid chromatography
- gene expression
- big data
- heart failure
- sensitive detection
- patient reported outcomes
- climate change
- intensive care unit
- dna methylation
- coronary artery disease
- toll like receptor
- hepatitis b virus
- fluorescent probe
- patient reported
- label free
- acute respiratory distress syndrome